<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01407276</url>
  </required_header>
  <id_info>
    <org_study_id>3102-009</org_study_id>
    <nct_id>NCT01407276</nct_id>
  </id_info>
  <brief_title>A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)</brief_title>
  <official_title>An Open-Label, Two-Part, Single-Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of MK-3102 in Patients With Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-part study in participants with renal impairment and matched healthy participants
      to investigate the effect of impaired renal function on the plasma and urine levels of
      omarigliptin (MK-3102) after taking a single 3 mg dose by mouth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Part I, three panels of 6 participants each will be enrolled with varying degrees of renal
      disease (mild, moderate, or severe renal impairment) based on their estimated glomerular
      filtration rate (eGFR). Each of these panels will be matched with a corresponding panel of
      equal number of healthy, age-, race-, BMI- and gender-matched control participants. All
      panels will receive a single oral dose of 3-mg omarigliptin, followed by plasma sampling and
      urine collection. In Part II, 6 participants with end stage renal disease (ESRD) requiring
      hemodialysis will receive a single 3-mg oral dose of omarigliptin immediately following
      hemodialysis (HD) (Period 1) and 2 hours prior to HD (Period 2).There will be approximately 1
      month between Period 1 and Period 2. A corresponding panel of equal number, healthy matched
      control subjects (age, race, BMI, gender) will also receive a single 3 mg dose by mouth.
      Omarigliptin dose administration will be followed by plasma sampling for both panels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2011</start_date>
  <completion_date type="Actual">March 23, 2012</completion_date>
  <primary_completion_date type="Actual">March 23, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) of Omarigliptin</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 (Panel G only), 96, 168, 240, and 336 hours post-dose</time_frame>
    <description>AUC0-∞ is a measure of the mean concentration levels of drug in the plasma after the dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of Omarigliptin</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 (Panel G only), 96, 168, 240, and 336 hours post-dose</time_frame>
    <description>Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time 0 to 168 Hours Post Dose (AUC0-168h) of Omarigliptin</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 (Panel G only), 96, and 168 hours post-dose</time_frame>
    <description>AUC0-168h is a measure of the total amount of drug in the plasma from the dose to 168 hours after the dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration at 168 Hours Post-dose (C168h) of Omarigliptin</measure>
    <time_frame>168 hours post-dose</time_frame>
    <description>C168h is a measure of the plasma drug concentration 168 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F) of Omarigliptin</measure>
    <time_frame>Up to 336 hours post-dose</time_frame>
    <description>Vd/F is defined as the distribution of a medication between the plasma and the rest of the body after the dose. It is the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of the drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Body Clearance (CL/F) of Omarigliptin</measure>
    <time_frame>Up to 336 hours post-dose</time_frame>
    <description>CL/F is a calculation of the rate at which a drug is removed from the body via renal, hepatic, and other clearance pathways, expressed as volume (milliliters) per unit of time (minutes).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CLr) of Omarigliptin</measure>
    <time_frame>Up to 336 hours post-dose</time_frame>
    <description>CLr is a calculation of the rate at which a drug is removed from the body via renal clearance pathways, expressed as volume (milliliters) per unit of time (minutes). CLr was only determined for Panels A-F.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fraction of Dose Excreted Unchanged in Urine Through 48 Hours Post-dose (fe48h) of Omarigliptin</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>fe48h is expressed as percentage of omarigliptin not metabolized and excreted in urine. fe48h was only determined for Panels A-F.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Amount of Drug Excreted in Urine Over 48 Hours (Ae0-48h) of Omarigliptin</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>Ae0-48h is a measure of the cumulative amount of drug excreted in the urine for 48 hours post-dose. Ae0-48h was only determined for Panels A-F.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of Omarigliptin</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 (Panel G only), 96, 168, 240, and 336 hours post-dose</time_frame>
    <description>Tmax is a measure of the time to reach the maximum drug plasma concentration post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Half-life (t1/2) of Omarigliptin</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 (Panel G only), 96, 168, 240, and 336 hours post-dose</time_frame>
    <description>T1/2 is the time required for the maximum concentration of a drug in the plasma to decrease by 50%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>From pre-dose to 14 days post-dose (Up to Day 15)</time_frame>
    <description>An AE was defined as any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a Sponsor product, whether or not considered related to the use of the product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Withdrawn From Study</measure>
    <time_frame>Up to Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Chronic Renal Insufficiency</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Part 1: Mild Renal Impairment (Panel A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Control to Match Panel A (Panel B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Moderate Renal Impairment (Panel C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Control to Match Panel C (Panel D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Severe Renal Impairment (Panel E)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Control to Match Panel E (Panel F)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: End-stage Renal Disease needing hemodialysis (Panel G)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Control to Match Panel G (Panel H)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omarigliptin</intervention_name>
    <description>Single oral dose of 3 mg (3 x 1-mg capsules)</description>
    <arm_group_label>Part 1: Mild Renal Impairment (Panel A)</arm_group_label>
    <arm_group_label>Part 1: Control to Match Panel A (Panel B)</arm_group_label>
    <arm_group_label>Part 1: Moderate Renal Impairment (Panel C)</arm_group_label>
    <arm_group_label>Part 1: Control to Match Panel C (Panel D)</arm_group_label>
    <arm_group_label>Part 1: Severe Renal Impairment (Panel E)</arm_group_label>
    <arm_group_label>Part 1: Control to Match Panel E (Panel F)</arm_group_label>
    <arm_group_label>Part 2: End-stage Renal Disease needing hemodialysis (Panel G)</arm_group_label>
    <arm_group_label>Part 2: Control to Match Panel G (Panel H)</arm_group_label>
    <other_name>MK-3102</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Impaired Renal Function Subjects:

          -  Females of reproductive potential must have a negative pregnancy test and agree to use
             2 methods of birth control

          -  Diagnosis of renal insufficiency based on estimated glomerular filtration rate (eGFR)
             calculated using the Modification of Diet in Renal Disease (MDRD) equation

        Healthy Subjects:

          -  Females of reproductive potential must have a negative pregnancy test and agree to use
             2 methods of birth control;

          -  In general good health

        Exclusion Criteria:

        Impaired Renal Function Subjects:

          -  Is mentally or legally incapacitated

          -  Has rapidly fluctuating renal function or has demonstrated or suspected renal artery
             stenosis

          -  History of significant endocrine (other than Type 2 diabetes), gastrointestinal,
             cardiovascular, hematological, immunological, respiratory, or genitourinary diseases

          -  History of stroke, chronic seizures or major neurological disease

          -  Uncontrolled Type 2 diabetes or history of Type 1 diabetes or ketoacidosis

          -  History of cancer (Some exceptions apply)

          -  Regular user of barbiturates or sleep aides

          -  Consumes excessive amounts of alcohol (more than 2 drinks/day)

          -  Consumes excessive amounts of caffeinated beverages (more than 6/day)

          -  Has had major surgery or has lost or donated 1 unit of blood within 4 weeks

          -  Has a history of significant multiple and/or severe allergies

          -  Current or history of illicit drug abuse

          -  Nursing mothers

        Healthy Subjects:

          -  Is mentally or legally incapacitated;

          -  Has a history of stroke, chronic seizures, or major neurological disorder

          -  Renal impairment

          -  History of clinically significant endocrine, gastrointestinal, cardiovascular,
             hematological, immunological, respiratory, or genitourinary diseases

          -  Hypoglycemia, glucose intolerance, Type 1 or Type 2 diabetes, or ketoacidosis

          -  History of cancer (Some exceptions apply)

          -  Regular user of barbiturates or sleep aides

          -  Consumes excessive amounts of alcohol (more than 2 drinks/day)

          -  Consumes excessive amounts of caffeinated beverages (more than 6/day)

          -  Has had major surgery or has lost or donated 1 unit of blood within 4 weeks

          -  Has a history of significant multiple and/or severe allergies

          -  Current or history of illicit drug abuse

          -  Nursing mothers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2011</study_first_submitted>
  <study_first_submitted_qc>July 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2011</study_first_posted>
  <results_first_submitted>September 29, 2015</results_first_submitted>
  <results_first_submitted_qc>October 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 3, 2015</results_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis Links</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=3102-009&amp;kw=3102-009&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One healthy matched control participant withdrew consent for study participation on Day 15; this participant was replaced. Thus, a total of 49 participants were in the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: Mild Renal Impairment (Panel A)</title>
          <description>Participants with estimated glomerular filtration rate (eGFR) ≥60 - &lt;80 mL/min/1.73 m² were enrolled in the Mild Renal Impairment group.</description>
        </group>
        <group group_id="P2">
          <title>Part 1: Control to Match Panel A (Panel B)</title>
          <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel A.</description>
        </group>
        <group group_id="P3">
          <title>Part 1: Moderate Renal Impairment (Panel C)</title>
          <description>Participants with eGFR ≥30 - &lt;60 mL/min/1.73 m² were enrolled in the Moderate Renal Impairment group.</description>
        </group>
        <group group_id="P4">
          <title>Part 1: Control to Match Panel C (Panel D)</title>
          <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel C.</description>
        </group>
        <group group_id="P5">
          <title>Part 1: Severe Renal Impairment (Panel E)</title>
          <description>Participants with eGFR &lt;30 mL/min/1.73 m² but not on dialysis were enrolled in the Severe Renal Impairment group.</description>
        </group>
        <group group_id="P6">
          <title>Part 1: Control to Match Panel E (Panel F)</title>
          <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel E.</description>
        </group>
        <group group_id="P7">
          <title>Part 2: ESRD Requiring HD (Panel G)</title>
          <description>Participants with end-stage renal disease (ESRD) requiring hemodialysis (HD)</description>
        </group>
        <group group_id="P8">
          <title>Part 2: Control to Match Panel G (Panel H)</title>
          <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel G.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1: Mild Renal Impairment (Panel A)</title>
          <description>Participants with estimated glomerular filtration rate (eGFR) ≥60 - &lt;80 mL/min/1.73 m² were enrolled in the Mild Renal Impairment group.</description>
        </group>
        <group group_id="B2">
          <title>Part 1: Control to Match Panel A (Panel B)</title>
          <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel A.</description>
        </group>
        <group group_id="B3">
          <title>Part 1: Moderate Renal Impairment (Panel C)</title>
          <description>Participants with eGFR ≥30 - &lt;60 mL/min/1.73 m² were enrolled in the Moderate Renal Impairment group.</description>
        </group>
        <group group_id="B4">
          <title>Part 1: Control to Match Panel C (Panel D)</title>
          <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel C.</description>
        </group>
        <group group_id="B5">
          <title>Part 1: Severe Renal Impairment (Panel E)</title>
          <description>Participants with eGFR &lt;30 mL/min/1.73 m² but not on dialysis were enrolled in the Severe Renal Impairment group.</description>
        </group>
        <group group_id="B6">
          <title>Part 1: Control to Match Panel E (Panel F)</title>
          <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel E.</description>
        </group>
        <group group_id="B7">
          <title>Part 2: ESRD Requiring HD (Panel G)</title>
          <description>Participants with end-stage renal disease (ESRD) requiring hemodialysis (HD)</description>
        </group>
        <group group_id="B8">
          <title>Part 2: Control to Match Panel G (Panel H)</title>
          <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel G.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="7"/>
            <count group_id="B9" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" lower_limit="67" upper_limit="75"/>
                    <measurement group_id="B2" value="68" lower_limit="64" upper_limit="74"/>
                    <measurement group_id="B3" value="62" lower_limit="50" upper_limit="74"/>
                    <measurement group_id="B4" value="60" lower_limit="51" upper_limit="74"/>
                    <measurement group_id="B5" value="64" lower_limit="54" upper_limit="72"/>
                    <measurement group_id="B6" value="60" lower_limit="51" upper_limit="69"/>
                    <measurement group_id="B7" value="46" lower_limit="36" upper_limit="60"/>
                    <measurement group_id="B8" value="43" lower_limit="33" upper_limit="57"/>
                    <measurement group_id="B9" value="59" lower_limit="33" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) of Omarigliptin</title>
        <description>AUC0-∞ is a measure of the mean concentration levels of drug in the plasma after the dose.</description>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 (Panel G only), 96, 168, 240, and 336 hours post-dose</time_frame>
        <population>All participants that received a single 3 mg dose of omarigliptin.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (Panel A)</title>
            <description>Participants with estimated glomerular filtration rate (eGFR) ≥60 - &lt;80 mL/min/1.73 m² were enrolled in the Mild Renal Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Control to Match Panel A (Panel B)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel A.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Moderate Renal Impairment (Panel C)</title>
            <description>Participants with eGFR ≥30 - &lt;60 mL/min/1.73 m² were enrolled in the Moderate Renal Impairment group.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Control to Match Panel C (Panel D)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Severe Renal Impairment (Panel E)</title>
            <description>Participants with eGFR &lt;30 mL/min/1.73 m² but not on dialysis were enrolled in the Severe Renal Impairment group.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Control to Match Panel E (Panel F)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel E.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: ESRD Requiring HD (Panel G) - Period 1</title>
            <description>Participants with end-stage renal disease (ESRD) requiring hemodialysis (HD) were enrolled in Panel G. In Period 1, participants received MK-3102 3 mg immediately after HD. One participant did not have an estimable parameter.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 1</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from the participant that withdrew from study was not included.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: ESRD Requiring HD (Panel G) - Period 2</title>
            <description>Participants with ESRD requiring HD were enrolled in Panel G. In Period 2, participants received MK-3102 3 mg 2 hours prior to HD.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 2</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from the participant that withdrew from study was not included.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) of Omarigliptin</title>
          <description>AUC0-∞ is a measure of the mean concentration levels of drug in the plasma after the dose.</description>
          <population>All participants that received a single 3 mg dose of omarigliptin.</population>
          <units>nM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4703.16" lower_limit="4078.19" upper_limit="5423.92"/>
                    <measurement group_id="O2" value="4983.58" lower_limit="4321.34" upper_limit="5747.31"/>
                    <measurement group_id="O3" value="5785.21" lower_limit="4950.03" upper_limit="6761.31"/>
                    <measurement group_id="O4" value="4312.17" lower_limit="3689.64" upper_limit="5039.74"/>
                    <measurement group_id="O5" value="6466.65" lower_limit="5577.34" upper_limit="7497.76"/>
                    <measurement group_id="O6" value="4142.94" lower_limit="3573.19" upper_limit="4803.53"/>
                    <measurement group_id="O7" value="7257.17" lower_limit="5595.73" upper_limit="9411.93"/>
                    <measurement group_id="O8" value="3842.62" lower_limit="2964.77" upper_limit="4980.39"/>
                    <measurement group_id="O9" value="7585.94" lower_limit="5852.93" upper_limit="9832.07"/>
                    <measurement group_id="O10" value="3842.62" lower_limit="2964.77" upper_limit="4980.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR</param_type>
            <param_value>0.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel C:Panel D</param_type>
            <param_value>1.34</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel E:Panel F</param_type>
            <param_value>1.56</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.32</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR or Panel G:Panel H</param_type>
            <param_value>1.89</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.40</ci_lower_limit>
            <ci_upper_limit>2.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel G:Panel H</param_type>
            <param_value>1.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.46</ci_lower_limit>
            <ci_upper_limit>2.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of Omarigliptin</title>
        <description>Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.</description>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 (Panel G only), 96, 168, 240, and 336 hours post-dose</time_frame>
        <population>All participants that received a single 3 mg dose of omarigliptin.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (Panel A)</title>
            <description>Participants with estimated glomerular filtration rate (eGFR) ≥60 - &lt;80 mL/min/1.73 m² were enrolled in the Mild Renal Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Control to Match Panel A (Panel B)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel A.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Moderate Renal Impairment (Panel C)</title>
            <description>Participants with eGFR ≥30 - &lt;60 mL/min/1.73 m² were enrolled in the Moderate Renal Impairment group.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Control to Match Panel C (Panel D)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Severe Renal Impairment (Panel E)</title>
            <description>Participants with eGFR &lt;30 mL/min/1.73 m² but not on dialysis were enrolled in the Severe Renal Impairment group.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Control to Match Panel E (Panel F)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel E.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: ESRD Requiring HD (Panel G) - Period 1</title>
            <description>Participants with end-stage renal disease (ESRD) requiring hemodialysis (HD) were enrolled in Panel G. In Period 1, participants received MK-3102 3 mg immediately after HD.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 1</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from one participant who withdrew from study and data from the replacement participant are both included.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: ESRD Requiring HD (Panel G) - Period 2</title>
            <description>Participants with ESRD requiring HD were enrolled in Panel G. In Period 2, participants received MK-3102 3 mg 2 hours prior to HD.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 2</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from one participant who withdrew from study and data from the replacement participant are both included.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Omarigliptin</title>
          <description>Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.</description>
          <population>All participants that received a single 3 mg dose of omarigliptin.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.37" spread="51.82" lower_limit="51.82" upper_limit="70.34"/>
                    <measurement group_id="O2" value="64.03" lower_limit="54.96" upper_limit="74.61"/>
                    <measurement group_id="O3" value="61.43" lower_limit="50.64" upper_limit="74.52"/>
                    <measurement group_id="O4" value="54.34" lower_limit="44.80" upper_limit="65.92"/>
                    <measurement group_id="O5" value="48.65" lower_limit="37.29" upper_limit="63.48"/>
                    <measurement group_id="O6" value="53.89" lower_limit="41.30" upper_limit="70.31"/>
                    <measurement group_id="O7" value="41.43" lower_limit="32.67" upper_limit="52.54"/>
                    <measurement group_id="O8" value="56.06" lower_limit="44.99" upper_limit="69.85"/>
                    <measurement group_id="O9" value="40.98" lower_limit="32.31" upper_limit="51.97"/>
                    <measurement group_id="O10" value="56.06" lower_limit="44.99" upper_limit="69.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel A:Panel B</param_type>
            <param_value>0.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel C:Panel D</param_type>
            <param_value>1.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel E:Panel F</param_type>
            <param_value>0.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel E:Panel F</param_type>
            <param_value>0.74</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel E:Panel F</param_type>
            <param_value>0.73</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time 0 to 168 Hours Post Dose (AUC0-168h) of Omarigliptin</title>
        <description>AUC0-168h is a measure of the total amount of drug in the plasma from the dose to 168 hours after the dose.</description>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 (Panel G only), 96, and 168 hours post-dose</time_frame>
        <population>All participants that received a single 3 mg dose of omarigliptin.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (Panel A)</title>
            <description>Participants with estimated glomerular filtration rate (eGFR) ≥60 - &lt;80 mL/min/1.73 m² were enrolled in the Mild Renal Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Control to Match Panel A (Panel B)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel A.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Moderate Renal Impairment (Panel C)</title>
            <description>Participants with eGFR ≥30 - &lt;60 mL/min/1.73 m² were enrolled in the Moderate Renal Impairment group.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Control to Match Panel C (Panel D)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Severe Renal Impairment (Panel E)</title>
            <description>Participants with eGFR &lt;30 mL/min/1.73 m² but not on dialysis were enrolled in the Severe Renal Impairment group.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Control to Match Panel E (Panel F)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel E.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: ESRD Requiring HD (Panel G) - Period 1</title>
            <description>Participants with end-stage renal disease (ESRD) requiring hemodialysis (HD) were enrolled in Panel G. In Period 1, participants received MK-3102 3 mg immediately after HD.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 1</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from one participant who withdrew from study and data from the replacement participant are both included.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: ESRD Requiring HD (Panel G) - Period 2</title>
            <description>Participants with ESRD requiring HD were enrolled in Panel G. In Period 2, participants received MK-3102 3 mg 2 hours prior to HD.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 2</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from one participant who withdrew from study and data from the replacement participant are both included.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time 0 to 168 Hours Post Dose (AUC0-168h) of Omarigliptin</title>
          <description>AUC0-168h is a measure of the total amount of drug in the plasma from the dose to 168 hours after the dose.</description>
          <population>All participants that received a single 3 mg dose of omarigliptin.</population>
          <units>nM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3055.48" lower_limit="2720.74" upper_limit="3431.42"/>
                    <measurement group_id="O2" value="3315.01" lower_limit="2951.83" upper_limit="3722.87"/>
                    <measurement group_id="O3" value="3674.50" lower_limit="3037.78" upper_limit="4444.68"/>
                    <measurement group_id="O4" value="2770.54" lower_limit="2290.46" upper_limit="3351.25"/>
                    <measurement group_id="O5" value="3580.02" lower_limit="3040.51" upper_limit="4215.27"/>
                    <measurement group_id="O6" value="2615.56" lower_limit="2221.40" upper_limit="3079.67"/>
                    <measurement group_id="O7" value="3352.27" lower_limit="2653.44" upper_limit="4235.17"/>
                    <measurement group_id="O8" value="2431.77" lower_limit="1958.50" upper_limit="3019.41"/>
                    <measurement group_id="O9" value="3150.93" lower_limit="2494.07" upper_limit="3980.80"/>
                    <measurement group_id="O10" value="2431.77" lower_limit="1958.50" upper_limit="3019.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel A:Panel B</param_type>
            <param_value>0.92</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel C:Panel D</param_type>
            <param_value>1.33</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel E:Panel F</param_type>
            <param_value>1.37</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel G:Panel H</param_type>
            <param_value>1.38</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel G:Panel H</param_type>
            <param_value>1.30</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration at 168 Hours Post-dose (C168h) of Omarigliptin</title>
        <description>C168h is a measure of the plasma drug concentration 168 hours post-dose.</description>
        <time_frame>168 hours post-dose</time_frame>
        <population>All participants that received a single 3 mg dose of omarigliptin.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (Panel A)</title>
            <description>Participants with estimated glomerular filtration rate (eGFR) ≥60 - &lt;80 mL/min/1.73 m² were enrolled in the Mild Renal Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Control to Match Panel A (Panel B)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel A.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Moderate Renal Impairment (Panel C)</title>
            <description>Participants with eGFR ≥30 - &lt;60 mL/min/1.73 m² were enrolled in the Moderate Renal Impairment group.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Control to Match Panel C (Panel D)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Severe Renal Impairment (Panel E)</title>
            <description>Participants with eGFR &lt;30 mL/min/1.73 m² but not on dialysis were enrolled in the Severe Renal Impairment group.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Control to Match Panel E (Panel F)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel E.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: ESRD Requiring HD (Panel G) - Period 1</title>
            <description>Participants with end-stage renal disease (ESRD) requiring hemodialysis (HD) were enrolled in Panel G. In Period 1, participants received MK-3102 3 mg immediately after HD.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 1</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from one participant who withdrew from study and data from the replacement participant are both included.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: ESRD Requiring HD (Panel G) - Period 2</title>
            <description>Participants with ESRD requiring HD were enrolled in Panel G. In Period 2, participants received MK-3102 3 mg 2 hours prior to HD.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 2</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from one participant who withdrew from study and data from the replacement participant are both included.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration at 168 Hours Post-dose (C168h) of Omarigliptin</title>
          <description>C168h is a measure of the plasma drug concentration 168 hours post-dose.</description>
          <population>All participants that received a single 3 mg dose of omarigliptin.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.19" lower_limit="6.06" upper_limit="8.53"/>
                    <measurement group_id="O2" value="7.85" lower_limit="6.62" upper_limit="9.31"/>
                    <measurement group_id="O3" value="9.10" lower_limit="7.68" upper_limit="10.78"/>
                    <measurement group_id="O4" value="6.28" lower_limit="5.30" upper_limit="7.44"/>
                    <measurement group_id="O5" value="11.48" lower_limit="9.64" upper_limit="13.69"/>
                    <measurement group_id="O6" value="6.28" lower_limit="5.27" upper_limit="7.49"/>
                    <measurement group_id="O7" value="11.46" lower_limit="8.81" upper_limit="14.91"/>
                    <measurement group_id="O8" value="6.05" lower_limit="4.74" upper_limit="7.71"/>
                    <measurement group_id="O9" value="11.35" lower_limit="8.72" upper_limit="14.76"/>
                    <measurement group_id="O10" value="6.05" lower_limit="4.74" upper_limit="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel A:Panel B</param_type>
            <param_value>0.92</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel C:Panel D</param_type>
            <param_value>1.45</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel E:Panel F</param_type>
            <param_value>1.83</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.49</ci_lower_limit>
            <ci_upper_limit>2.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel G:Panel H</param_type>
            <param_value>1.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.41</ci_lower_limit>
            <ci_upper_limit>2.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel G:Panel H</param_type>
            <param_value>1.88</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.40</ci_lower_limit>
            <ci_upper_limit>2.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (Vd/F) of Omarigliptin</title>
        <description>Vd/F is defined as the distribution of a medication between the plasma and the rest of the body after the dose. It is the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of the drug.</description>
        <time_frame>Up to 336 hours post-dose</time_frame>
        <population>All participants that received a single 3 mg dose of omarigliptin.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (Panel A)</title>
            <description>Participants with estimated glomerular filtration rate (eGFR) ≥60 - &lt;80 mL/min/1.73 m² were enrolled in the Mild Renal Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Control to Match Panel A (Panel B)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel A.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Moderate Renal Impairment (Panel C)</title>
            <description>Participants with eGFR ≥30 - &lt;60 mL/min/1.73 m² were enrolled in the Moderate Renal Impairment group.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Control to Match Panel C (Panel D)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Severe Renal Impairment (Panel E)</title>
            <description>Participants with eGFR &lt;30 mL/min/1.73 m² but not on dialysis were enrolled in the Severe Renal Impairment group.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Control to Match Panel E (Panel F)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel E.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: ESRD Requiring HD (Panel G) - Period 1</title>
            <description>Participants with end-stage renal disease (ESRD) requiring hemodialysis (HD) were enrolled in Panel G. In Period 1, participants received MK-3102 3 mg immediately after HD. One participant did not have an estimable parameter.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 1</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from the participant that withdrew from study was not included.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: ESRD Requiring HD (Panel G) - Period 2</title>
            <description>Participants with ESRD requiring HD were enrolled in Panel G. In Period 2, participants received MK-3102 3 mg 2 hours prior to HD.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 2</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from the participant that withdrew from the study was not included.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vd/F) of Omarigliptin</title>
          <description>Vd/F is defined as the distribution of a medication between the plasma and the rest of the body after the dose. It is the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of the drug.</description>
          <population>All participants that received a single 3 mg dose of omarigliptin.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349.42" lower_limit="282.17" upper_limit="432.69"/>
                    <measurement group_id="O2" value="314.39" lower_limit="253.88" upper_limit="389.31"/>
                    <measurement group_id="O3" value="295.86" lower_limit="218.39" upper_limit="400.82"/>
                    <measurement group_id="O4" value="392.75" lower_limit="289.90" upper_limit="532.08"/>
                    <measurement group_id="O5" value="280.58" lower_limit="216.30" upper_limit="363.95"/>
                    <measurement group_id="O6" value="410.21" lower_limit="316.24" upper_limit="532.11"/>
                    <measurement group_id="O7" value="334.57" lower_limit="249.27" upper_limit="449.07"/>
                    <measurement group_id="O8" value="478.52" lower_limit="357.04" upper_limit="641.32"/>
                    <measurement group_id="O9" value="383.12" lower_limit="285.87" upper_limit="513.47"/>
                    <measurement group_id="O10" value="478.52" lower_limit="357.04" upper_limit="641.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel A:Panel B</param_type>
            <param_value>1.11</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel C:Panel D</param_type>
            <param_value>0.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel E:Panel F</param_type>
            <param_value>0.68</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel G:Panel H</param_type>
            <param_value>0.70</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel G:Panel H</param_type>
            <param_value>0.80</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Total Body Clearance (CL/F) of Omarigliptin</title>
        <description>CL/F is a calculation of the rate at which a drug is removed from the body via renal, hepatic, and other clearance pathways, expressed as volume (milliliters) per unit of time (minutes).</description>
        <time_frame>Up to 336 hours post-dose</time_frame>
        <population>All participants that received a single 3 mg dose of omarigliptin.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (Panel A)</title>
            <description>Participants with estimated glomerular filtration rate (eGFR) ≥60 - &lt;80 mL/min/1.73 m² were enrolled in the Mild Renal Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Control to Match Panel A (Panel B)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel A.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Moderate Renal Impairment (Panel C)</title>
            <description>Participants with eGFR ≥30 - &lt;60 mL/min/1.73 m² were enrolled in the Moderate Renal Impairment group.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Control to Match Panel C (Panel D)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Severe Renal Impairment (Panel E)</title>
            <description>Participants with eGFR &lt;30 mL/min/1.73 m² but not on dialysis were enrolled in the Severe Renal Impairment group.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Control to Match Panel E (Panel F)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel E.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: ESRD Requiring HD (Panel G) - Period 1</title>
            <description>Participants with end-stage renal disease (ESRD) requiring hemodialysis (HD) were enrolled in Panel G. In Period 1, participants received MK-3102 3 mg immediately after HD. One participant did not have an estimable parameter.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 1</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from the participant that withdrew from study was not included.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: ESRD Requiring HD (Panel G) - Period 2</title>
            <description>Participants with ESRD requiring HD were enrolled in Panel G. In Period 2, participants received MK-3102 3 mg 2 hours prior to HD.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 2</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from the participant that withdrew from study was not included.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance (CL/F) of Omarigliptin</title>
          <description>CL/F is a calculation of the rate at which a drug is removed from the body via renal, hepatic, and other clearance pathways, expressed as volume (milliliters) per unit of time (minutes).</description>
          <population>All participants that received a single 3 mg dose of omarigliptin.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.51" lower_limit="22.98" upper_limit="30.57"/>
                    <measurement group_id="O2" value="25.02" lower_limit="21.69" upper_limit="28.85"/>
                    <measurement group_id="O3" value="21.55" lower_limit="18.44" upper_limit="25.18"/>
                    <measurement group_id="O4" value="28.91" lower_limit="24.74" upper_limit="33.79"/>
                    <measurement group_id="O5" value="19.28" lower_limit="16.63" upper_limit="22.35"/>
                    <measurement group_id="O6" value="30.09" lower_limit="25.95" upper_limit="34.89"/>
                    <measurement group_id="O7" value="17.18" lower_limit="13.25" upper_limit="22.28"/>
                    <measurement group_id="O8" value="32.44" lower_limit="25.03" upper_limit="42.05"/>
                    <measurement group_id="O9" value="16.43" lower_limit="12.68" upper_limit="21.30"/>
                    <measurement group_id="O10" value="32.44" lower_limit="25.03" upper_limit="42.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel A:Panel B</param_type>
            <param_value>1.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel C:Panel D</param_type>
            <param_value>0.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel E:Panel F</param_type>
            <param_value>0.64</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel G:Panel H</param_type>
            <param_value>0.53</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel G:Panel H</param_type>
            <param_value>0.51</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Clearance (CLr) of Omarigliptin</title>
        <description>CLr is a calculation of the rate at which a drug is removed from the body via renal clearance pathways, expressed as volume (milliliters) per unit of time (minutes). CLr was only determined for Panels A-F.</description>
        <time_frame>Up to 336 hours post-dose</time_frame>
        <population>All participants that received a single 3 mg dose of omarigliptin.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (Panel A)</title>
            <description>Participants with estimated glomerular filtration rate (eGFR) ≥60 - &lt;80 mL/min/1.73 m² were enrolled in the Mild Renal Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Control to Match Panel A (Panel B)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel A.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Moderate Renal Impairment (Panel C)</title>
            <description>Participants with eGFR ≥30 - &lt;60 mL/min/1.73 m² were enrolled in the Moderate Renal Impairment group.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Control to Match Panel C (Panel D)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Severe Renal Impairment (Panel E)</title>
            <description>Participants with eGFR &lt;30 mL/min/1.73 m² but not on dialysis were enrolled in the Severe Renal Impairment group.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Control to Match Panel E (Panel F)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel E.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CLr) of Omarigliptin</title>
          <description>CLr is a calculation of the rate at which a drug is removed from the body via renal clearance pathways, expressed as volume (milliliters) per unit of time (minutes). CLr was only determined for Panels A-F.</description>
          <population>All participants that received a single 3 mg dose of omarigliptin.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.26" lower_limit="22.25" upper_limit="33.41"/>
                    <measurement group_id="O2" value="29.27" lower_limit="23.89" upper_limit="35.87"/>
                    <measurement group_id="O3" value="17.93" lower_limit="14.06" upper_limit="22.87"/>
                    <measurement group_id="O4" value="24.71" lower_limit="19.37" upper_limit="31.52"/>
                    <measurement group_id="O5" value="12.18" lower_limit="9.79" upper_limit="15.14"/>
                    <measurement group_id="O6" value="28.84" lower_limit="23.19" upper_limit="35.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel A:Panel B</param_type>
            <param_value>0.93</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel C:Panel D</param_type>
            <param_value>0.73</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel E:Panel F</param_type>
            <param_value>0.42</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fraction of Dose Excreted Unchanged in Urine Through 48 Hours Post-dose (fe48h) of Omarigliptin</title>
        <description>fe48h is expressed as percentage of omarigliptin not metabolized and excreted in urine. fe48h was only determined for Panels A-F.</description>
        <time_frame>Up to 48 hours post-dose</time_frame>
        <population>All participants that received a single 3 mg dose of omarigliptin.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (Panel A)</title>
            <description>Participants with estimated glomerular filtration rate (eGFR) ≥60 - &lt;80 mL/min/1.73 m² were enrolled in the Mild Renal Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Control to Match Panel A (Panel B)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel A.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Moderate Renal Impairment (Panel C)</title>
            <description>Participants with eGFR ≥30 - &lt;60 mL/min/1.73 m² were enrolled in the Moderate Renal Impairment group.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Control to Match Panel C (Panel D)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Severe Renal Impairment (Panel E)</title>
            <description>Participants with eGFR &lt;30 mL/min/1.73 m² but not on dialysis were enrolled in the Severe Renal Impairment group.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Control to Match Panel E (Panel F)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel E.</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Dose Excreted Unchanged in Urine Through 48 Hours Post-dose (fe48h) of Omarigliptin</title>
          <description>fe48h is expressed as percentage of omarigliptin not metabolized and excreted in urine. fe48h was only determined for Panels A-F.</description>
          <population>All participants that received a single 3 mg dose of omarigliptin.</population>
          <units>Percentage of total dose</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="29" upper_limit="43"/>
                    <measurement group_id="O2" value="41" lower_limit="34" upper_limit="50"/>
                    <measurement group_id="O3" value="27" lower_limit="22" upper_limit="33"/>
                    <measurement group_id="O4" value="30" lower_limit="24" upper_limit="37"/>
                    <measurement group_id="O5" value="15" lower_limit="12" upper_limit="20"/>
                    <measurement group_id="O6" value="31" lower_limit="24" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel A:Panel B</param_type>
            <param_value>0.86</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel C:Panel D</param_type>
            <param_value>0.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel E:Panel F</param_type>
            <param_value>0.50</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Amount of Drug Excreted in Urine Over 48 Hours (Ae0-48h) of Omarigliptin</title>
        <description>Ae0-48h is a measure of the cumulative amount of drug excreted in the urine for 48 hours post-dose. Ae0-48h was only determined for Panels A-F.</description>
        <time_frame>Up to 48 hours post-dose</time_frame>
        <population>All participants that received a single 3 mg dose of omarigliptin.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (Panel A)</title>
            <description>Participants with estimated glomerular filtration rate (eGFR) ≥60 - &lt;80 mL/min/1.73 m² were enrolled in the Mild Renal Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Control to Match Panel A (Panel B)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel A.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Moderate Renal Impairment (Panel C)</title>
            <description>Participants with eGFR ≥30 - &lt;60 mL/min/1.73 m² were enrolled in the Moderate Renal Impairment group.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Control to Match Panel C (Panel D)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Severe Renal Impairment (Panel E)</title>
            <description>Participants with eGFR &lt;30 mL/min/1.73 m² but not on dialysis were enrolled in the Severe Renal Impairment group.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Control to Match Panel E (Panel F)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel E.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Amount of Drug Excreted in Urine Over 48 Hours (Ae0-48h) of Omarigliptin</title>
          <description>Ae0-48h is a measure of the cumulative amount of drug excreted in the urine for 48 hours post-dose. Ae0-48h was only determined for Panels A-F.</description>
          <population>All participants that received a single 3 mg dose of omarigliptin.</population>
          <units>mg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="0.86" upper_limit="1.25"/>
                    <measurement group_id="O2" value="1.21" lower_limit="1.00" upper_limit="1.46"/>
                    <measurement group_id="O3" value="0.79" lower_limit="0.64" upper_limit="0.98"/>
                    <measurement group_id="O4" value="0.88" lower_limit="0.71" upper_limit="1.10"/>
                    <measurement group_id="O5" value="0.45" lower_limit="0.35" upper_limit="0.58"/>
                    <measurement group_id="O6" value="0.90" lower_limit="0.70" upper_limit="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel A:Panel B</param_type>
            <param_value>0.86</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel C:Panel D</param_type>
            <param_value>0.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMR of Panel E:Panel F</param_type>
            <param_value>0.50</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Concentration (Tmax) of Omarigliptin</title>
        <description>Tmax is a measure of the time to reach the maximum drug plasma concentration post-dose.</description>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 (Panel G only), 96, 168, 240, and 336 hours post-dose</time_frame>
        <population>All participants that received a single 3 mg dose of omarigliptin.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (Panel A)</title>
            <description>Participants with estimated glomerular filtration rate (eGFR) ≥60 - &lt;80 mL/min/1.73 m² were enrolled in the Mild Renal Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Control to Match Panel A (Panel B)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel A.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Moderate Renal Impairment (Panel C)</title>
            <description>Participants with eGFR ≥30 - &lt;60 mL/min/1.73 m² were enrolled in the Moderate Renal Impairment group.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Control to Match Panel C (Panel D)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Severe Renal Impairment (Panel E)</title>
            <description>Participants with eGFR &lt;30 mL/min/1.73 m² but not on dialysis were enrolled in the Severe Renal Impairment group.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Control to Match Panel E (Panel F)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel E.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: ESRD Requiring HD (Panel G) - Period 1</title>
            <description>Participants with end-stage renal disease (ESRD) requiring hemodialysis (HD) were enrolled in Panel G. In Period 1, participants received MK-3102 3 mg immediately after HD.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 1</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from one participant who withdrew from study and data from the replacement participant are both included.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: ESRD Requiring HD (Panel G) - Period 2</title>
            <description>Participants with ESRD requiring HD were enrolled in Panel G. In Period 2, participants received MK-3102 3 mg 2 hours prior to HD.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 2</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from one participant who withdrew from study and data from the replacement participant are both included.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration (Tmax) of Omarigliptin</title>
          <description>Tmax is a measure of the time to reach the maximum drug plasma concentration post-dose.</description>
          <population>All participants that received a single 3 mg dose of omarigliptin.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O4" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O6" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O7" value="4.0" lower_limit="2.0" upper_limit="6.0"/>
                    <measurement group_id="O8" value="1.0" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O9" value="4.0" lower_limit="1.0" upper_limit="6.2"/>
                    <measurement group_id="O10" value="1.0" lower_limit="0.5" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Half-life (t1/2) of Omarigliptin</title>
        <description>T1/2 is the time required for the maximum concentration of a drug in the plasma to decrease by 50%.</description>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 (Panel G only), 96, 168, 240, and 336 hours post-dose</time_frame>
        <population>All participants that received a single 3 mg dose of omarigliptin.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (Panel A)</title>
            <description>Participants with estimated glomerular filtration rate (eGFR) ≥60 - &lt;80 mL/min/1.73 m² were enrolled in the Mild Renal Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Control to Match Panel A (Panel B)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel A.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Moderate Renal Impairment (Panel C)</title>
            <description>Participants with eGFR ≥30 - &lt;60 mL/min/1.73 m² were enrolled in the Moderate Renal Impairment group.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Control to Match Panel C (Panel D)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Severe Renal Impairment (Panel E)</title>
            <description>Participants with eGFR &lt;30 mL/min/1.73 m² but not on dialysis were enrolled in the Severe Renal Impairment group.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Control to Match Panel E (Panel F)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel E.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: ESRD Requiring HD (Panel G) - Period 1</title>
            <description>Participants with end-stage renal disease (ESRD) requiring hemodialysis (HD) were enrolled in Panel G. In Period 1, participants received MK-3102 3 mg immediately after HD. One participant did not have an estimable parameter.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 1</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from the participant that withdrew from study was not included.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: ESRD Requiring HD (Panel G) - Period 2</title>
            <description>Participants with ESRD requiring HD were enrolled in Panel G. In Period 2, participants received MK-3102 3 mg 2 hours prior to HD.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 2</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from the participant that withdrew from study was not included.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2) of Omarigliptin</title>
          <description>T1/2 is the time required for the maximum concentration of a drug in the plasma to decrease by 50%.</description>
          <population>All participants that received a single 3 mg dose of omarigliptin.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.3" spread="39.0"/>
                    <measurement group_id="O2" value="143.7" spread="21.9"/>
                    <measurement group_id="O3" value="156.2" spread="32.0"/>
                    <measurement group_id="O4" value="147.0" spread="65.4"/>
                    <measurement group_id="O5" value="159.8" spread="55.7"/>
                    <measurement group_id="O6" value="155.0" spread="33.5"/>
                    <measurement group_id="O7" value="215.4" spread="38.7"/>
                    <measurement group_id="O8" value="162.6" spread="53.7"/>
                    <measurement group_id="O9" value="263.7" spread="62.7"/>
                    <measurement group_id="O10" value="162.6" spread="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing an Adverse Event (AE)</title>
        <description>An AE was defined as any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a Sponsor product, whether or not considered related to the use of the product.</description>
        <time_frame>From pre-dose to 14 days post-dose (Up to Day 15)</time_frame>
        <population>All participants that received a single 3 mg dose of omarigliptin.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (Panel A)</title>
            <description>Participants with estimated glomerular filtration rate (eGFR) ≥60 - &lt;80 mL/min/1.73 m² were enrolled in the Mild Renal Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Control to Match Panel A (Panel B)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel A.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Moderate Renal Impairment (Panel C)</title>
            <description>Participants with eGFR ≥30 - &lt;60 mL/min/1.73 m² were enrolled in the Moderate Renal Impairment group.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Control to Match Panel C (Panel D)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Severe Renal Impairment (Panel E)</title>
            <description>Participants with eGFR &lt;30 mL/min/1.73 m² but not on dialysis were enrolled in the Severe Renal Impairment group.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Control to Match Panel E (Panel F)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel E.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: ESRD Requiring HD (Panel G) - Periods 1 and 2</title>
            <description>Participants with end-stage renal disease (ESRD) requiring hemodialysis (HD) were enrolled in Panel G.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 1</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from one participant who withdrew from study and data from the replacement participant are both included.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing an Adverse Event (AE)</title>
          <description>An AE was defined as any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a Sponsor product, whether or not considered related to the use of the product.</description>
          <population>All participants that received a single 3 mg dose of omarigliptin.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Withdrawn From Study</title>
        <time_frame>Up to Day 15</time_frame>
        <population>All participants that received a single 3 mg dose of omarigliptin.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (Panel A)</title>
            <description>Participants with estimated glomerular filtration rate (eGFR) ≥60 - &lt;80 mL/min/1.73 m² were enrolled in the Mild Renal Impairment group.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Control to Match Panel A (Panel B)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel A.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Moderate Renal Impairment (Panel C)</title>
            <description>Participants with eGFR ≥30 - &lt;60 mL/min/1.73 m² were enrolled in the Moderate Renal Impairment group.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Control to Match Panel C (Panel D)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel C.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Severe Renal Impairment (Panel E)</title>
            <description>Participants with eGFR &lt;30 mL/min/1.73 m² but not on dialysis were enrolled in the Severe Renal Impairment group.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Control to Match Panel E (Panel F)</title>
            <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel E.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: ESRD Requiring HD (Panel G) - Periods 1 and 2</title>
            <description>Participants with end-stage renal disease (ESRD) requiring hemodialysis (HD) were enrolled in Panel G.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Control to Match Panel G (Panel H) - Period 1</title>
            <description>Participants were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from one participant who withdrew from study and data from the replacement participant are both included.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Withdrawn From Study</title>
          <population>All participants that received a single 3 mg dose of omarigliptin.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From pre-dose to 14 days post-dose (up to Day 15)</time_frame>
      <desc>An adverse experience is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1: Mild Renal Impairment (Panel A)</title>
          <description>Participants with estimated glomerular filtration rate (eGFR) ≥60 - &lt;80 mL/min/1.73 m² were enrolled in the Mild Renal Impairment group.</description>
        </group>
        <group group_id="E2">
          <title>Part 1: Control to Match Panel A (Panel B)</title>
          <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel A.</description>
        </group>
        <group group_id="E3">
          <title>Part 1: Moderate Renal Impairment (Panel C)</title>
          <description>Participants with eGFR ≥30 - &lt;60 mL/min/1.73 m² were enrolled in the Moderate Renal Impairment group.</description>
        </group>
        <group group_id="E4">
          <title>Part 1: Control to Match Panel C (Panel D)</title>
          <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel C.</description>
        </group>
        <group group_id="E5">
          <title>Part 1: Severe Renal Impairment (Panel E)</title>
          <description>Participants with eGFR &lt;30 mL/min/1.73 m² but not on dialysis were enrolled in the Severe Renal Impairment group.</description>
        </group>
        <group group_id="E6">
          <title>Part 1: Control to Match Panel E (Panel F)</title>
          <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel E.</description>
        </group>
        <group group_id="E7">
          <title>Part 2: ESRD Requiring HD (Panel G)</title>
          <description>Participants with end-stage renal disease (ESRD) requiring hemodialysis (HD)</description>
        </group>
        <group group_id="E8">
          <title>Part 2: Control to Match Panel G (Panel H)</title>
          <description>Participants with eGFR &gt;/= 80 mL/min/1.73 m² were matched by age, gender, race, and body mass index (BMI) to participants in Panel G. Data from one participant who withdrew from study and data from the replacement participant are both included.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v.15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eccymosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

